Hengrui Pharma(SH:600276) Zhong Guo Jin Rong Xin Xi Wang·2025-07-09 10:19Core Viewpoint - The Hong Kong stock market has experienced a decline, with the Hang Seng Index dropping by 1.06% and the Hang Seng Tech Index falling by 1.76% in July, while A-shares have been rising, leading to a rebound in the AH share premium [1] Group 1: Market Performance - The Hang Seng Index and Hang Seng Tech Index recorded declines in July, contrasting with the upward trend in A-shares, particularly the Shanghai Composite Index approaching 3500 points [1] - As of July 9, the AH share premium has rebounded to 130.64, an increase of over 2% from mid-June [1] Group 2: Individual Stock Performance - Among the 160 AH shares, only three companies—CATL, Hengrui Medicine, and WuXi AppTec—are trading at a premium for their H-shares compared to A-shares, with CATL's premium exceeding 30% and Hengrui Medicine's over 11% [1][2] - CATL's H-shares have risen nearly 17% in July, while its A-shares increased by 7.37%, leading to an expanding premium [2][3] - Hengrui Medicine's H-shares have surged over 29% since their listing on May 23, while A-shares rose by 10.19%, resulting in a significant premium for H-shares [3] Group 3: Market Dynamics - The market dynamics indicate that CATL and Hengrui Medicine are core assets in the domestic new energy and innovative drug sectors, attracting significant capital in the Hong Kong market [3] - The liquidity of H-shares for both companies is considerably lower than that of A-shares, making it easier to drive up H-share prices [4] Group 4: Recent Developments - CATL has signed a comprehensive electrification deepening strategic cooperation agreement with Geely Auto, focusing on battery technology collaboration and supply chain development [4] - Hengrui Medicine has received approval for clinical trials of two new drugs, with one targeting chronic obstructive pulmonary disease (COPD), indicating a strong pipeline of innovative drugs [5]